General Overview

Previously the Diagnostic division of Systagenix, WOUNDCHEK™ Laboratories is focused on the development of novel wound diagnostics products to help improve therapeutic outcomes in wound care. Currently, the cost of ineffective treatment is estimated to be $20-25 billion¹Data based on savings calculated with the WOUNDCHEK economic model, UK version, with AQP VLU data inputs. – Nherera L. et al. Quantifying the economic value of diagnostics in wound care in the UK. Poster, EWMA 2013. annually. Clinical experts agree the use of point of care wound diagnostic devices could reduce the cost of ineffective treatment and delayed healing by being able to target the right therapy, on the right patient, at the right time, and for the right length of time²World Union of Wound Healing Societies (WUWHS). Principles of best practice: Diagnostics and wounds. A consensus document. London: MEP Ltd, 2008.. A resulting financial benefit to health care systems can be achieved through significant reduction of the expenses associated with poor targeting of treatment, delayed healing, and avoidable complications. WOUNDCHEK™ Laboratories launched the world’s first and only point of care test to detect EPA (elevated protease activity) in chronic wounds in 2012, and over the past several years has become a recognized leader in wound diagnostics. 

Mission

The company’s vision is to provide clinicians with better, accurate, timely, actionable, and easy to access information, leading to improved therapeutic outcomes through point of care wound diagnostics. WOUNDCHEK™ Laboratories aims to be the leading and dominant enterprise in wound diagnostics by providing medical professionals with the diagnostic information to: 

  • Identify wounds which are not healing 

  • Intercept issues and early warnings that cause poor wound healing or initiate wounds 

  • Aid in determination of best therapeutic routes 

  • Monitor the effectiveness of a course of treatment

Activities

Based in the UK and the USA, WOUNDCHEK™ Laboratories' staff are focused on product development, clinical research, and working with its distribution partners to develop the emerging wound diagnostics markeg.

Our research is centred on two critical questions, identified by clinical experts as primary pieces of diagnostic information needed to direct treatment pathways in the majority of chronic wounds:

  • Does the wound have Elevated Protease Activity?

  • Is there an active infection?

WOUNDCHEK™ Protease Status, the world’s first and only point of care test to detect EPA (elevated protease activity), was launched in 2012 and cleared for sale in Europe, the Middle East, South Africa, and Canada.

 

ISO 9001:2008 and ISO 13485:2003 certified quality management system.

Infection

Bacterial Load

Bacterial Pathogenesis

Microbial Species

Biofilms

Host Response

Bacterial Resistance

Healing

Proteases

ECM Proteins

Inflammatory Mediators

Nitric Oxide

Growth Factors

Markers

Physical/Chemical

Temperature

Pressure

pH

Size

Colour

Smell

Preventative Measures

Genetic Markers

Genetic Polymorphisms

Neuropathy

Areas of Interest

The strategy of WOUNDCHEK™ Laboratories is to be the leading and dominant enterprise in wound care diagnostics by providing medical professionals with the diagnostic information to: 

  • Identify wounds which are not healing

  • Intercept issues and early warnings that cause poor wound healing or initiate wounds

  • Aid in determination of best therapeutic routes

  • Monitor the effectiveness of a course of treatment

Clinical experts identified numerous markers that could form the basis of new diagnostic tools for use in wound care1World Union of Wound Healing Societies (WUWHS). Principles of best practice: Diagnosis and wounds. A consensus document. London: MEP Ltd, 2008.(see slide above).

  • Jack Wilkens

    Jack Wilkens

    Chief Executive Officer

  • Simon Bayliff

    Simon Bayliff

    Vice President, R&D

  • Malcolm Williams

    Malcolm Williams

    Chief Financial Officer

  • Patrick Brosnan

    Patrick Brosnan

    Scientist

  • Gill Witherington

    Gill Witherington

    Administrator

  • Bob Dicheck

    Bob Dicheck

    Regulatory

  • Richard Collette

    Richard Collette

    Commercial

  • Jack Wilkens

    Jack Wilkens

    Chief Executive Officer

  • Leon Okurowski

    Leon Okurowski

     

  • Bill Umphrey

    Bill Umphrey

     

Jack Wilkens
Chief Executive Officer

Former Systagenix Vice President of Diagnostics Development, CEO of RevDia, which specializes in infectious disease point of care diagnostic testing. Prior to RevDia, he was Chief Operating Officer for Inverness Medical Innovations (now Alere - ALR-NYSE), a world leader in point of care rapid diagnostics. He has also held senior management positions with Unipath, IMI, Sterling Diagnostics / AGFA and Polaroid Corporation. Mr. Wilkens has a BS in Chemical Engineering and an MBA.

Simon Bayliff
Vice President, Research & Development

Simon is a Biochemistry & Physiology graduate with nearly 30 years' experience developing products in the Medical Device and In-Vitro Diagnostic fields. He has worked in 'start-up' environments and for companies including Abbott Laboratories and Johnson & Johnson.

Patrick Brosnan, BSc
Scientist

Patrick has worked in wound care for the past five years, with Systagenix. He worked for four years as an R&D scientist and more recently has moved into the clinical side of the company, helping run, monitor and analyse trials in USA. Patrick graduated from The University of Manchester in 2008 with a BSc (hons) in Biology. 

Gill Witherington
Administrator

Gill has worked in admin for 13 years in Gargrave, firstly for Johnson & Johnson, which then became Systagenix Wound Management for the Research & Development Department and has to be able to deal with a vast range of tasks.

Malcolm Williams
Chief Financial Officer

Malcolm is a fellow of the chartered institute of management accountants (UK) as well as having an honours degree in accountancy and finance. He spent 22 years with Johnson and Johnson working mainly in medical devices and diagnostics. Latterly he was the international finance director for Ortho Clinical Diagnostics covering Europe, Africa and Asia. He now works for several start up businesses.

Bob Dicheck
Regulatory

Bob Dicheck is an experienced regulatory and quality management professional, who has been involved in U.S. and international regulated industries for more than 30 years.

Previously he was Vice President of Quality & Regulatory Affairs for Osmetech Molecular Diagnostics and Vice President Worldwide QA/RA at Unipath, Inverness Medical Innovations. Prior to that Bob held a variety of corporate and global franchise executive level QA/RA positions over 14 years within the Johnson & Johnson family of companies.

Richard Collette
Commercial

Richard Collette is an experienced Commercial Business Leader in international business development for medical products such as diagnostic imaging equipment, tele-care for chronic wound management, IVDs, and implantable devices covering the past 20 years.

Most recently, he was President of the USA and Canada marketing, sales, distribution, and service operation for one of the leading suppliers of implants that restore hearing to those challenged with profound hearing loss.

Jack Wilkens
Chief Executive Officer

Former Systagenix Vice President of Diagnostics Development, CEO of RevDia, which specializes in infectious disease point of care diagnostic testing. Prior to RevDia, he was Chief Operating Officer for Inverness Medical Innovations (now Alere - ALR-NYSE), a world leader in point of care rapid diagnostics. He has also held senior management positions with Unipath, IMI, Sterling Diagnostics / AGFA and Polaroid Corporation. Mr. Wilkens has a BS in Chemical Engineering and an MBA.

Leon Okurowski

Mr. Okurowski is the Vice President of Pear Tree Advisors and the co-founder and Vice-President of the Pear Tree Funds. He is also Vice President and Treasurer for various U.S. Boston entities. Mr. Okurowski has over forty years experience in the finance and investment management business.

Mr. Okurowski obtained his MBA from the Whittemore School of Business at the Univerity of New Hampshire, his MS in taxation from Bentley College, and a BS from the United States Naval Academy.

He has served on the boards of several high-tech companies. He was a co-founder and served on theboard of Atlantic Bank and Trust
Company, a public company.

Prior to joining U.S. Boston,
Mr. Okurowski served in the
United States Navy as a
submarine officer.

Bill Umphrey

Mr. Umphrey is the Chairman and co-founder of the Pear Tree Funds, the President of Pear Tree Advisors, Inc., and the Chairman of U.S. Boston Capital Corporation. Mr. Umphrey founded the U.S. Boston's predecessor in 1969 and has over forty years of experience in the finance and investment management business.

Mr. Umphrey obtained his JD from Harvard Law School, an LLM in taxation from Boston University of Law, a Masters in Personnel Administration fron George Washington Univeristy, and a BS with distiction from the United States Naval Academy in Annapolis, Maryland.

Prior to founding U.S. Boston,
Mr. Umphrey served in the
United States Navy as a
submarine officer.

Events icon Events

Date: Sep 8, 2016

WOUNDCHEK™ Protease Status receives market clearance in Australia


WOUNDCHEK™ Laboratories announced today that WOUNDCHEK™ Protease Status, the world's first point of care wound diagnostic for chronic wounds, has received market clearance from the Australian Therapeutic Goods Administration.

Read More

WOUNDCHEK™ Protease Status receives market clearance in Australia

Fall River, MA, USA – September 5, 2016 – WOUNDCHEK™ Laboratories announced today that WOUNDCHEK™ Protease Status, the world’s first point of care wound diagnostic for chronic wounds, has received market clearance from the Australian Therapeutic Goods Administration. Intermed Medical Pty Ltd has been appointed as distributor for the product in Australia and New Zealand.

WOUNDCHEK™ Protease Status, already available in Europe, Canada & South Africa, detects a chronic inflammatory response in the wound, as indicated by elevated human protease activity (EPA) and was developed to help guide treatment decisions to enable improved outcomes and more cost effective care. “Protease activity is an essential part of wound healing.  However, once out of control, and if left unchecked, proteases in wounds may cause sufficient damage.… to impair healing and destroy normal tissue.”  (Wounds International Consensus “The role of proteases in wound healing”, 2011, pp1).

Also currently in clinical trial is a new point of care test to detect when bacteria in the wound have become pathogenic, as indicated by bacterial protease activity (BPA).  This test will help identify wounds in which bacteria may be delaying healing, which could assist clinicians in determining when interventions to reduce bacterial burden are indicated, particularly in chronic wounds with no obvious signs of infection.

Jack Wilkens, CEO of WOUNDCHEK™ Laboratories, commented: “We are delighted with the news that our first product has been cleared for sale in Australia and will be distributed by Intermed Medical Pty Ltd, a company with a strong track record in marketing innovative wound care products. Currently, the global cost of ineffective treatment is estimated to be $20-25 billion annually. Our vision is to provide clinicians with accurate, timely, actionable, and easy to access information, leading to improved therapeutic outcomes and more cost effective care through point of care wound diagnostics.”

 

For more information, contact:

Richard Collette at WOUNDCHEK™ Laboratories on richard.collette@woundchek.com

Or

Australia: Ben Darling at Intermed Medical on ben.darling@intermedmedical.com.au

New Zealand: Ashley Witheford at Intermed Medical on ashley.witheford@intermed.co.nz

Close

Icon Address Contact Us

WOUNDCHEK™ Laboratories

Airebank Mill
Gargrave; BD23 3RX
North Yorkshire
United Kingdom

T: +44 (0) 1756 639111

Icon EmailE: info@woundchek.com

Technical Helpline:
+800 1558 8551

Icon PrintMap & Directions
From the North
From the South West
From the South East

This is a captcha-picture. It is used to prevent mass-access by robots. (see: www.captcha.net)
Contact Woundchek